JP6903585B2 - 補体関連疾患の治療のための組成物および治療方法 - Google Patents

補体関連疾患の治療のための組成物および治療方法 Download PDF

Info

Publication number
JP6903585B2
JP6903585B2 JP2017548107A JP2017548107A JP6903585B2 JP 6903585 B2 JP6903585 B2 JP 6903585B2 JP 2017548107 A JP2017548107 A JP 2017548107A JP 2017548107 A JP2017548107 A JP 2017548107A JP 6903585 B2 JP6903585 B2 JP 6903585B2
Authority
JP
Japan
Prior art keywords
complement
dimethoxy
dihydroquinazoline
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017548107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507899A (ja
JP2018507899A5 (OSRAM
Inventor
シルヴィア・ヴァシャク
エヴェリナ・ビー・クリコフスキー
クリストファー・アール・エイ・ハリデイ
ディーン・ギラム
ローラ・エム・ツジカワ
Original Assignee
レスバーロジックス コーポレイション
レスバーロジックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスバーロジックス コーポレイション, レスバーロジックス コーポレイション filed Critical レスバーロジックス コーポレイション
Publication of JP2018507899A publication Critical patent/JP2018507899A/ja
Publication of JP2018507899A5 publication Critical patent/JP2018507899A5/ja
Application granted granted Critical
Publication of JP6903585B2 publication Critical patent/JP6903585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017548107A 2015-03-13 2016-03-10 補体関連疾患の治療のための組成物および治療方法 Active JP6903585B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562132572P 2015-03-13 2015-03-13
US62/132,572 2015-03-13
US201562264768P 2015-12-08 2015-12-08
US62/264,768 2015-12-08
PCT/IB2016/000443 WO2016147053A1 (en) 2015-03-13 2016-03-10 Compositions and therapeutic methods for the treatment of complement-associated diseases

Publications (3)

Publication Number Publication Date
JP2018507899A JP2018507899A (ja) 2018-03-22
JP2018507899A5 JP2018507899A5 (OSRAM) 2019-04-18
JP6903585B2 true JP6903585B2 (ja) 2021-07-14

Family

ID=56886497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548107A Active JP6903585B2 (ja) 2015-03-13 2016-03-10 補体関連疾患の治療のための組成物および治療方法

Country Status (9)

Country Link
US (2) US10111885B2 (OSRAM)
EP (1) EP3268007B1 (OSRAM)
JP (1) JP6903585B2 (OSRAM)
KR (1) KR102662814B1 (OSRAM)
CN (2) CN114984016A (OSRAM)
CA (1) CA2977308A1 (OSRAM)
JO (1) JO3789B1 (OSRAM)
TW (1) TWI705815B (OSRAM)
WO (1) WO2016147053A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
CN114984016A (zh) * 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
US11965884B2 (en) * 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
ES2888904T3 (es) 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
JP7281470B2 (ja) * 2018-01-19 2023-05-25 イドーシア ファーマシューティカルズ リミテッド Ｃ５ａ受容体調節剤
CN108484510B (zh) * 2018-05-18 2020-05-05 东南大学 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
JP7502811B2 (ja) * 2019-11-05 2024-06-19 レスバーロジックス コーポレイション Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法
WO2021154941A1 (en) * 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
KR20230041758A (ko) * 2020-07-20 2023-03-24 애넥슨, 인코포레이티드 보체 인자의 저해제 및 이의 용도
CN113754594B (zh) * 2021-09-16 2025-01-21 中国药科大学 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
WO2025193888A1 (en) * 2024-03-14 2025-09-18 Vanqua Bio, Inc. Pyridazinone c5ar1 antagonists and uses thereof

Family Cites Families (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2065593A (en) 1936-12-29 Water-soluble diazoimino com
FR472489A (fr) 1914-02-20 1914-12-08 Stas Motor Ges M B H Bague de garniture métallique pour pistons
US2065900A (en) 1935-03-23 1936-12-29 Gen Aniline Works Inc Dihydroxystilbene-dicarboxylic acid and a process of preparing it
US2071329A (en) 1935-08-22 1937-02-23 Solvay Process Co Method of recovering phthalic anhydride
GB728767A (en) 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
GB1179019A (en) 1967-05-23 1970-01-28 Produits Chimique Soc Et Polynicotinic Esters of Flavonoids
FR6928M (OSRAM) 1967-11-24 1969-05-05
US3600394A (en) 1968-05-17 1971-08-17 Searle & Co 2-aminoalkyl-3-arylisocarbostyrils
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
FR2244493A1 (en) 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE2349024A1 (de) 1973-09-26 1975-04-10 Schering Ag 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione
IT1050750B (it) 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
US5098903A (en) 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
EP0182213B1 (en) 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Carbapenem compounds and production thereof
DE3515882A1 (de) 1985-05-03 1986-11-06 Dr. Karl Thomae Gmbh, 7950 Biberach Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung
DE3532279A1 (de) 1985-09-11 1987-03-12 Bayer Ag 1,4-benzoxathiin-derivate
DE3601417A1 (de) 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
US4825005A (en) 1986-08-29 1989-04-25 Ciba-Geigy Corporation Process for the preparation of aromatic ether and thioether compounds
ES2053508T3 (es) 1986-11-24 1994-08-01 Fujisawa Pharmaceutical Co Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
GB8804058D0 (en) 1988-02-22 1988-03-23 Fujisawa Pharmaceutical Co 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds
US4925838A (en) 1988-03-18 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
US4963544A (en) 1988-05-23 1990-10-16 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
GB8926981D0 (en) 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
FR2649612A1 (fr) 1989-07-17 1991-01-18 Rhone Poulenc Sante Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation
IE64358B1 (en) 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
GB9018134D0 (en) 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
EP0485636B1 (en) 1990-06-05 1997-03-12 Toray Industries, Inc. Indole derivative
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
IE913866A1 (en) 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
GB9025832D0 (en) 1990-11-28 1991-01-09 Ashwell Geoffrey J Novel films for nonlinear optical applications
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
CA2085136C (en) 1991-04-10 1997-03-18 Ernest Kun Method for inhibition of retroviral replication
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
FR2689127B1 (fr) 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
DE4215587A1 (de) 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
DE4215588A1 (de) 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH0680656A (ja) 1992-09-03 1994-03-22 Mitsui Petrochem Ind Ltd 光学活性エポキシドの製造方法
AU5850894A (en) 1992-12-23 1994-07-19 Procept, Inc. Novel agents for inhibition of hiv infectivity and use therefor
JPH0741442A (ja) 1993-05-21 1995-02-10 Sumitomo Chem Co Ltd アセチレンアルコール誘導体およびその製造法
JPH0761942A (ja) 1993-06-17 1995-03-07 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH0725761A (ja) 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
US5756763A (en) 1993-07-23 1998-05-26 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Pyrrolidine derivatives
US5707547A (en) 1993-08-03 1998-01-13 Sumitomo Chemical Company, Limited Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition
JPH07118241A (ja) 1993-09-01 1995-05-09 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH07179380A (ja) 1993-12-22 1995-07-18 Sumitomo Chem Co Ltd アルコール誘導体およびその製造法
JPH07233109A (ja) 1994-02-24 1995-09-05 Sumitomo Chem Co Ltd 光学活性なアルコール誘導体およびその製造法
WO1995023150A1 (en) 1994-02-25 1995-08-31 Banyu Pharmaceutical Co., Ltd. Carbapenem derivative
EP0749974B1 (en) 1994-03-08 2001-06-27 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
JPH07247289A (ja) 1994-03-11 1995-09-26 Mitsui Petrochem Ind Ltd クロメンオキシド類の製造方法
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
JP3702493B2 (ja) 1994-08-12 2005-10-05 大正製薬株式会社 キナゾリン−４（３ｈ）−オン誘導体
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
JP4140981B2 (ja) 1994-12-26 2008-08-27 東菱薬品工業株式会社 再狭窄症及び動脈硬化症治療薬
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
ES2180702T3 (es) 1995-06-07 2003-02-16 Lilly Co Eli Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
US5922866A (en) 1995-08-30 1999-07-13 Otsuka Pharmaceutical Factory, Inc. Process for preparing quinazolin-4-one derivatives
AU4858596A (en) 1995-09-15 1997-04-01 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997015308A1 (en) 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
US5756736A (en) 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5739330A (en) 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
US5763608A (en) 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
BR9707425A (pt) 1996-02-12 1999-07-20 Univ Rutgers Composto processo terapêutico para inibir o crescimento de células cancerosas e processo para utilizar o composto
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100213895B1 (ko) 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
DE19651099A1 (de) 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JPH10287678A (ja) 1997-04-11 1998-10-27 Kyowa Hakko Kogyo Co Ltd ピラノアジン誘導体
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
EP1009404A4 (en) 1997-05-13 2009-07-01 Octamer Inc PROCESS FOR TREATING INFLAMMATION OR INFLAMMATORY DISEASES USING POLY-ADP RIBOSE POLYMERASE INHIBITORS
DK0988038T3 (da) 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
TW450964B (en) 1997-08-29 2001-08-21 Takeda Schering Plough Animal Triazine derivatives, their production and use
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6239114B1 (en) 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
EP1020445B1 (en) 1997-10-02 2008-08-13 Eisai R&D Management Co., Ltd. Fused pyridine derivatives
DE69817862T2 (de) 1997-10-28 2004-07-15 Korea Institute Of Science And Technology Naringin und naringenin als mittel zur vorbeugung oder behandlung von leber-erkrankungen
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
CA2316808C (en) 1998-01-08 2007-04-10 Aventis Pharmaceuticals Products Inc. Transgenic rabbit that expresses a functional human lipoprotein (a)
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
PT1108435E (pt) 1998-08-24 2007-04-30 Chugai Pharmaceutical Co Ltd Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CA2345311A1 (en) 1998-09-24 2000-03-30 Kazutoshi Watanabe Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
KR20010103583A (ko) 1998-10-19 2001-11-23 다니구치 미즈오 진통제
CN1327384A (zh) 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
US6433187B1 (en) 1998-12-17 2002-08-13 Tularik Inc. Certain polycyclic compounds useful as tubulin-binding agents
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
JP2002539217A (ja) 1999-03-15 2002-11-19 アボット・ラボラトリーズ 抗菌活性を有する６−ｏ−置換マクロライド
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
US6835755B1 (en) 1999-06-24 2004-12-28 University Of Pretoria Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
JP2001131151A (ja) 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
CN1319959C (zh) 1999-12-06 2007-06-06 天济药业（深圳）有限公司 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物
FR2804679B1 (fr) 2000-02-07 2002-04-26 Clariant France Sa Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application
ATE272600T1 (de) 2000-02-17 2004-08-15 Appleton Paper Inc Verfahren zur herstellung von alkoxy- oder arylmethoxy-aroxyethanen
WO2003018008A1 (en) 2000-02-25 2003-03-06 Shionogi & Co., Ltd. Apo ai expression accelerating agent
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
WO2003024441A1 (en) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Novel use of tricyclic compound
US6479499B1 (en) 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
JP2002047283A (ja) 2000-07-04 2002-02-12 Basf Ag 新規フラボノイドおよびそれらの化粧用または皮膚科用製品における使用
US6541522B2 (en) 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
JP2004510767A (ja) 2000-10-02 2004-04-08 モレキュラー・プロウブズ・インコーポレーテッド アルデヒド部分またはケトン部分を有する生物分子を標識するための試薬
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
MXPA03003002A (es) 2000-10-05 2004-12-06 Fujisawa Pharmaceutical Co Compuestos de benzamina como inhibidores de la secrecion de la apo b.
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
JP2004532799A (ja) 2000-10-11 2004-10-28 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物
AU2002232381B2 (en) 2000-10-19 2004-11-18 Merck & Co., Inc. Estrogen receptor modulators
CN1285601C (zh) 2000-11-30 2006-11-22 佳能株式会社 发光器件和显示器
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
KR100472694B1 (ko) 2000-12-30 2005-03-07 한국생명공학연구원 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
JP2002249483A (ja) 2001-02-21 2002-09-06 Koei Chem Co Ltd アリール置換複素環式化合物の製造法
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
CA2444429A1 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
US20030211086A1 (en) * 2001-06-05 2003-11-13 Neil Berkley Minicell-based selective absorption
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
GB0118752D0 (en) 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
WO2003016292A1 (en) 2001-08-13 2003-02-27 Ciba Specialty Chemicals Holding Inc. Ultraviolet light absorbers
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6835469B2 (en) 2001-10-17 2004-12-28 The University Of Southern California Phosphorescent compounds and devices comprising the same
US7250512B2 (en) 2001-11-07 2007-07-31 E. I. Du Pont De Nemours And Company Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds
US7166368B2 (en) 2001-11-07 2007-01-23 E. I. Du Pont De Nemours And Company Electroluminescent platinum compounds and devices made with such compounds
US6541045B1 (en) 2002-01-04 2003-04-01 Nutraceutical Corporation Herbal composition and method for combating inflammation
US8367824B2 (en) 2002-01-28 2013-02-05 Ube Industries Ltd. Process for producing quinazolin-4-one derivative
EP1478357B1 (en) 2002-02-19 2007-01-31 Pfizer Italia S.r.l. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
NZ556545A (en) 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
KR20040001144A (ko) 2002-06-27 2004-01-07 김대경 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20040033480A1 (en) 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
CN1671639A (zh) 2002-08-23 2005-09-21 康涅狄格大学 新型联苯大麻素和类似联苯的大麻素
US20040176366A1 (en) 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
US7074810B2 (en) 2002-10-07 2006-07-11 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
AU2003291761A1 (en) 2002-11-04 2004-06-07 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
WO2004046152A1 (en) 2002-11-18 2004-06-03 F. Hoffmann La Roche Ag Diazinopyrimidines
MXPA05005425A (es) 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
MXPA05006124A (es) 2002-12-13 2005-08-16 Hoffmann La Roche Derivados de 3-quinazolin-4-ona.
ITRM20020629A1 (it) 2002-12-19 2004-06-20 Sigma Tau Ind Farmaceuti Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
CA2520323C (en) 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
DE602004019518D1 (de) 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
JP5044214B2 (ja) 2003-06-06 2012-10-10 アレクシス・アクチボラゲット 皮膚状態または癌の処置のためのｓｃｃｅ阻害剤としての縮合複素環化合物の使用
US7314939B2 (en) 2003-06-17 2008-01-01 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
WO2004113307A1 (ja) 2003-06-18 2004-12-29 Ube Industries, Ltd. ピリミジン−４−オン化合物の製造方法
US20050043300A1 (en) 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
CN1925862A (zh) 2003-10-10 2007-03-07 雷斯弗洛吉克斯公司 与egr－1增强子元件有关的疾病的治疗
RU2006112343A (ru) 2003-10-28 2007-12-10 Редди Юс Терапеутикс, Инк. (Us) Гетероциклические соединения и способы их получения и применения
US20070060601A1 (en) 2003-12-19 2007-03-15 Arrington Kenneth L Mitotic kinesin inhibitors
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
EP1757594A4 (en) 2004-05-31 2007-12-12 Banyu Pharma Co Ltd quinazoline derivative
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006012577A2 (en) 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
US20070218155A1 (en) 2004-08-20 2007-09-20 Kuhrts Eric H Methods and compositions for treating dyslipidaemia
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
US20070004763A1 (en) * 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
AU2006329202A1 (en) 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CA2621134C (en) 2006-05-12 2011-07-26 Pharmathen S.A. Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
US20100055173A1 (en) 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
CA2669867A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
ATE524487T1 (de) * 2007-01-11 2011-09-15 Univ Ramot Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
ES2308916B1 (es) 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
EP2005941A3 (de) 2007-06-01 2009-04-01 Henkel AG & Co. KGaA Zellverjüngende Zusammensetzungen
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
CN101687821A (zh) 2007-06-21 2010-03-31 Irm责任有限公司 蛋白激酶抑制剂及其使用方法
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
MX2011003328A (es) 2008-10-06 2011-06-20 Carolus Therapeutics Inc Metodos para tratar inflamacion.
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
US20100183598A1 (en) 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
TW201035083A (en) 2009-03-06 2010-10-01 Hoffmann La Roche Heterocyclic antiviral compounds
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
ES2353093B1 (es) 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
UA109797C2 (uk) 2010-11-05 2015-10-12 Спосіб боротьби з бур'янами, що мають стійкість до гербіцидів на основі феноксіалканових кислот, за допомогою 4-аміно-3-хлор-6-(4-хлор-2-фтор-3-метоксифеніл)піридин-2-карбонової кислоти і її солей або складних ефірів
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012112531A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
SG11201401082XA (en) 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
JP5992049B2 (ja) * 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US20130281398A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
WO2014062428A1 (en) 2012-10-15 2014-04-24 Albemarle Corporation Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
MX338885B (es) 2012-10-15 2016-05-04 Resverlogix Corp Compuestos utiles en la sintesis de compuestos de benzamida.
WO2014080290A2 (en) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
AU2014205553A1 (en) 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
WO2014134583A2 (en) 2013-02-28 2014-09-04 Washington University Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
BR112015022417A2 (pt) 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
WO2014154606A1 (en) 2013-03-27 2014-10-02 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
CN105473145A (zh) * 2013-08-21 2016-04-06 雷斯韦洛吉克斯公司 用于加速斑块消退的组合物和治疗方法
CN105473144A (zh) 2013-08-21 2016-04-06 雷斯韦洛吉克斯公司 用于加速斑块消退的组合物和治疗方法
US9814728B2 (en) 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
EP3689420A1 (en) 2014-01-23 2020-08-05 H. Lee Moffitt Cancer Center & Research Institute, Inc. Icariin derivatives for use in treating myelodysplasia syndrome
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
WO2016123054A2 (en) 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2016145294A1 (en) 2015-03-12 2016-09-15 The University Of Chicago Methods for determining prognosis for breast cancer patients
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CA2985203A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Targeted selection of patients for treatment with cortistatin derivatives
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN106265679A (zh) 2015-06-28 2017-01-04 复旦大学 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途
US9896663B2 (en) 2016-03-11 2018-02-20 Peter Maccallum Cancer Institute Leukaemia stem cell line, its method of production and uses thereof
CN106176753A (zh) 2016-07-15 2016-12-07 南方医科大学 Rvx‑208作为hiv‑1潜伏感染逆转剂的应用
US10158038B1 (en) * 2018-05-17 2018-12-18 Hi Llc Fast-gated photodetector architectures comprising dual voltage sources with a switch configuration

Also Published As

Publication number Publication date
EP3268007A4 (en) 2018-11-07
US10772894B2 (en) 2020-09-15
KR20170123696A (ko) 2017-11-08
CN114984016A (zh) 2022-09-02
TW201639574A (zh) 2016-11-16
US10111885B2 (en) 2018-10-30
US20160263126A1 (en) 2016-09-15
WO2016147053A1 (en) 2016-09-22
TWI705815B (zh) 2020-10-01
EP3268007B1 (en) 2022-11-09
JO3789B1 (ar) 2021-01-31
JP2018507899A (ja) 2018-03-22
US20190091235A1 (en) 2019-03-28
CA2977308A1 (en) 2016-09-22
KR102662814B1 (ko) 2024-05-03
CN107530356A (zh) 2018-01-02
EP3268007A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
JP6903585B2 (ja) 補体関連疾患の治療のための組成物および治療方法
Li et al. Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3
AU2019240646B2 (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
RU2627268C2 (ru) Аза-арил-1Н-пиразол-1-ил-сульфонамиды
KR102586710B1 (ko) C5a 억제제로서의 5-5 융합 고리
JP2022508751A (ja) Ｐｆｋｆｂ３阻害剤とその使用
TWI507191B (zh) 含ｓｒｃ同源區２蛋白酪胺酸磷酸酶－１增效劑及其治療方法
EA017110B1 (ru) ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
JP2017537946A (ja) ブロモドメイン阻害剤としての置換複素環
JP7457360B2 (ja) 線維症の処置
CN112239459B (zh) 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
JP2023504194A (ja) インスリン耐性における使用方法のための治療化合物
US11046657B2 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
JP2001513503A (ja) 心臓血管系の疾病の治療に用いられるマクロファージスカベンジャー受容体アンタゴニスト
CN118440056A (zh) 基于crbn配体诱导irak4降解的化合物及其制备方法和应用
US11369609B2 (en) Small molecule Wnt inhibitor as treatment for dyslipidemia
HK1241295A1 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
HK1241295B (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
JP5210153B2 (ja) 新規特異的カスパーゼ−１０阻害剤
JP2013544292A (ja) 狼瘡の処置のためのヤーヌスキナーゼ２（ｊａｋ２）インヒビタ
HK40074114A (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
HK40074114B (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2025037010A1 (en) Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
JP2005247743A (ja) 基礎代謝調節剤、及びそのスクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210428

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210623

R150 Certificate of patent or registration of utility model

Ref document number: 6903585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250